Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAR441000 intratumoral study alone and with cemiplimab in advanced solid tumors
NL-OMON55221Phase 1Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of SAR441000 and cemiplimab in Nonhematologic neoplasms, melanoma, cutaneous squamous cell carcinoma (cSCC) and 3 more (3 arms), sponsored by Sanofi. Primary endpoints: Dose-limiting toxicities and Objective response rate. Started Jul 2021; status: active, not recruiting.
02
Drugs
SAR441000cemiplimab
03
Conditions
Nonhematologic neoplasmsmelanomacutaneous squamous cell carcinoma (cSCC)head and neck squamous cell carcinoma (HNSCC)lymphoma
Beyond the preview
Go deeper on NL-OMON55221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55221.